ANZCTR search results

These search results are from the Australian New Zealand Clinical Trials Registry (ANZCTR).

You can narrow down the results using the filters

34128 results sorted by trial registration date.
  • An open, phase Ia safety and dosing clinical trial evaluating IMD-101 in participants with advanced solid tumours.

    This study is evaluating the safety, dosing, absorption and distribution of IMD-101, an innovative anti-cancer immunotherapy drug, in patients with advanced malignant solid tumours. Who is it for? You may be eligible for this study if you are an adult with histologically or cytologically confirmed advanced malignant solid tumours, including melanoma, non-small cell lung cancer (NSCLC), renal cell cancer, mesothelioma, and bladder cancer, and have failed standard of care treatment. IMD-101 is given 20 microgram/kg by intravenous infusion every 2 weeks for 3 times. When it's safe to do, 40 microgram, 80 microgram, 120 microgram, 180 microgram, or 240 microgram will be tested sequentially. Participants will also be asked to attend to visits for up to 6 weeks following commencement of IMD-101 for blood and urine tests, and physical examinations.

  • Single-institution, single-arm, open-label phase II basket study of mutation and/or elevated hedgehog (Hh) expression-directed smoothened inhibitor sonidegib in patients with advanced solid malignancies

    The purpose of the study is to investigate whether Sonidegib (an anti-cancer drug) is effective and safe to use in patients with advanced solid organ cancers that have a specific SMO/PTCH1 gene mutation or elevated Hedgehog protein levels. Who is it for? This study will involve an initial screening phase followed by an intervention/treatment phase. You may be eligible for the screening study if you are aged 18 years or older, you have been diagnosed with advanced solid organ cancer apart from advanced basal cell carcinoma and you have received at least one prior cancer treatment. Treatment naïve Individuals with a solid organ cancer that has no standard treatment may be eligible to screen. If the screening study identifies that your particular cancer expresses an SMO/PTCH1 gene mutation or an elevated Hedgehog protein level, you may be eligible to participate in the treatment phase. Additional health assessments to check your liver, kidney and heart function will be undertaken to determine eligibility for the treatment study. Study details All participants who chose to enrol in this study will firstly undergo an initial screening phase. This screening phase will involve providing a blood sample for testing, as well as allowing the study investigators to access previously collected tissue samples of your cancer for testing. Participants who meet the eligibility criteria for the treatment phase will be enrolled and asked to take an oral tablet, containing the study drug, Sonidegib, each day for a minimum of 8 weeks. Any participants who experience severe side effects while taking the study drug will be asked to stop taking the drug. Participants who do not experience severe side effects will be asked to continue taking the drug for a maximum of 12 months, unless they experience any spread of their cancer or later develop severe side effects to the drug. Participants will be asked to undergo CT scans once every 8 weeks while taking the study drug. It is hoped this research will determine whether a new anti-cancer treatment, Sonidegib, is safe to use in people with advanced solid cancers. If the drug is safe and is shown to reduce the size or activity of cancer cells in these patients, a larger randomised trial to assess the effect of Sonidegib may be undertaken.

  • Effect of Loading on Breathing Behaviour, Muscle Activation, and Performance During Unstable versus Stable Load Resistance Training

    The primary goal of this acute study is to compare breathing behaviour across various loads during parallel back squats between unstable load training (ULT) and traditional training (TRAD). Secondary objectives involve investigating the effects of stable versus unstable conditions across various loads on muscle activation, exercise stability, mechanical performance and perceptual fatigue. The primary hypothesis is that there will be a greater inspiratory volume, a higher rate of breaths, a longer duration of breath-holding, and a larger expiratory volume with an increase in load during squats in both the ULT and TRAD conditions.

  • Cognitive appraisal and stress response comparisons of final year paramedicine students

    In health-related disciplines such as nursing and medicine, practical assessment centre around high acuity simulated patients. In the emerging field of undergraduate paramedicine education, little research has explored this type of assessment nor the associated physiological and cognitive stress. We don't know whether this stress enhances or hinders learning? Acute stress response is well known to lead to performance degradation, so are these students being set up to fail when really educators should be encouraging learning as a priority. Research must be undertaken to determine how much physiological and cognitive stress is too much. Our hypothesis is that students who appraise a scenario as a threat will perform at a lower clinical ability than those who adopt a challenge appraisal.

  • The feasibility of using Electrical Impedance Tomography to determine mechanics of ventilation in comparison to standard clinical parameters in patients with high spinal injury T8 and above

    The general aim of this pilot study is to establish correlations between parameters of electrical impedance tomography with standard clinical parameters. The specific aims are to: 1.Assess lung ventilation distribution in patients with high spinal injuries (T8 and above) 2.Collect clinical data on ventilatory mechanics including level of spinal deficits, ventilatory mechanics (invasive, non-invasive, ventilator settings) intraabdominal pressure, FiO2 ratio, and end tidal CO2 to arterial CO2 gap 3.Assess correlation between EIT parameters and clinical data Validity and reliability of EIT systems has been demonstrated in several studies, indicating that EIT may be effective in the assessment of ventilation distribution in patients with asthma, COPD and cystic fibrosis. Furthermore, EIT has also compared well with lung measures such as lung volumes and lung density quantified by CT. However, there is currently little or no studies of the use of EIT in monitoring of patients with restrictive lung disease, in particular patients with spinal injuries.

  • Max Up - Comparing uptake of lung cancer screening and smoking cessation outcomes in Quitline clients receiving 3 months vs 12 months of smoking cessation Nicotine Replacement Therapy and counselling.

    This purpose of this study is to assess the effectiveness of using Quitline as a referral pathway into lung cancer screening, and to assess whether combining Nicotine Replacement Therapy and Quitline telephone counselling interventions in current smokers is effective for people at risk of lung cancer. Who is it for? You may be eligible for this trial if you are aged between 50 – 80 years old, have a Prostate Lung Colorectal Ovarian model 2012 (PLCOm2012) score of >=1.51% and are a person who currently smokes with a 20-pack year smoking history. The PLCOm2012 model has been developed for lung cancer detection, and a score of >=1.51% means you are eligible for lung cancer screening. Study details Participants will be randomly allocated by chance (similar to flipping a coin) to the intervention group or the control group. Participants allocated to the intervention will be receive Nicotine Replacement Therapy and Quitline telephone counselling interventions for 12 months. While those participants who are randomised into the control group will Nicotine Replacement Therapy and Quitline telephone counselling interventions for 12 weeks (3 months). Participants who are eligible for lung cancer screening (based on certain criteria [PLCOm2012 > 1.5%, Have a > 20 pack year smoking history), will have a free CT scan of the lungs (within 12 months of enrolment in the study). Questionnaires will be collected every three months for the first year to assess the acceptability of the intervention and then once a year for 4 years to assess patient reported outcomes. It is hoped this intervention will help design a national Australian Lung Cancer Screening Program.

  • Investigating Mental and Physical Health Approaches for Supporting Men with Depression and Overweight or Obesity: A Feasibility Trial

    Depression and obesity in men are two of the largest public health concerns in Australia. These conditions also appear to be linked as men with overweight or obesity are ~30% more likely to develop depression than healthy weight men. Furthermore, men with depression are 43% more likely to develop obesity than men without depression. The SHED-IT: Recharge randomised trial (ACTRN12619001209189) tested a self-guided eHealth program combining lifestyle behaviour change advice and mental health support to reduce depression (and weight status) in men. It was the first RCT of an integrated mental and physical health intervention for men with depression. Results indicated significant and clinically meaningful intervention effects on both depressive symptoms and weight loss at post-intervention compared to the control group, which was maintained at 6-month follow up. However, because the program targeted physical and mental health it was unclear which components were most important for driving changes in the men's depressive symptoms. As such, the purpose of this pilot trial is the examine the feasibility and preliminary efficacy of comparing an online program focused only on lifestyle behaviour change to an online program focused only on mental health support for men with depression and overweight or obesity.

  • The Australian Endometriosis Clinicians Collaborative (AECC): adenomyosis substudy

    Like endometriosis, adenomyosis is a benign uterine disorder and is histologically defined by presence of endometrial tissue in the myometrium (muscle layer) of the uterus. The prevalence of adenomyosis is difficult to determine, since histological confirmation is necessary following surgical biopsy or more commonly hysterectomy. For women wanting to retain their uterus, hysterectomy is not an option. Imaging technologies (e.g. transvaginal ultrasound and MRI), are used as a less invasive method of diagnosis and detection, although they have limitations. The Australian Endometriosis Clinicians Collaborative (AECC): adenomyosis substudy is a prospective longitudinal clinical study that will: 1. compare diagnosis and treatment of adenomyosis with regards to impact on pain, bleeding patterns, general health symptoms and quality of life using validated questionnaires 2. determine cost-effectiveness of diagnostic and treatment options 3. establish a national biobank of adenomyosis (and endometriosis) for future research capacity. Outcomes will determine optimised diagnosis and treatment pathways for clinicians that improve quality of life for women with adenomyosis.

  • The CHILL BONES trial: testing Tai Chi and high intensity resistance and impact training (HiRIT) as therapy for older adults with low bone mass.

    Ageing results in gradual loss of bone mass, which increases our risk of fracture. Increased stress responses are also associated with ageing and may contribute to accelerated bone loss. This study will be the first to investigate whether Tai Chi (a gentle, mind-body exercise) is able to reduce stress responses and optimise osteoporosis rehabilitation outcomes (i.e. improve bone mass, falls risk) when practised in combination with high-intensity resistance and impact exercise.

  • Effectiveness of aspirin in children undergoing heart surgery

    A significant number of neonates and infants require systemic-to-pulmonary artery shunt procedures as a part of staged treatment of their congenital cardiac condition. These shunts are at risk of thrombotic occlusion. Shunt patency is critical for survival of these children. The interim mortality of shunt dependent children has been found to be as high as 14%, and about 33% of these are due to thrombosis of the shunt. Some eventually undergo correction of their cardiac anomalies while the remaining undergo further surgeries for a single ventricle palliation (Fontan pathway). The children with single ventricle palliation are dependent on the patency of their subsequent shunts for survival. They are at risk of life-threatening thrombosis throughout their lives. Cross-sectional surveys of post-Fontan patients have reported a prevalence of intracardiac thrombosis of 17% to 33% and incidences of venous thrombosis and stroke ranging from 3% to 19%. The reported mortality from post-Fontan surgery thromboembolism is 25%. Aspirin has been the cornerstone of thromboprophylaxis in such children and its use has been associated with a significantly lower risk of mortality. Unfortunately, not all children respond equally to aspirin with an increase in the dose of aspirin suggested to reduce the incidence of thrombosis in some while the remaining have no response to aspirin. The prevalence of aspirin unresponsiveness in adults is estimated to be 0.4 to 35%, however this information in lacking in the paediatric population. The primary objective of the study is therefore to determine the prevalence of aspirin resistance in children undergoing cardiac surgery in Queensland. Secondary objectives are: 1) to assess if response to aspirin is dose dependent and 2) assess the incidence of thrombosis in children who respond to aspirin.

Tags:
  • Finding clinical trials